Rh isoimmunization in sub-saharan africa indicates need for universal access to anti-rhd immunoglobulin and effective management of d-negative pregnancies

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 429-437

  Osaro, Erhabor ^a   Charles, Adias Teddy ^b  

^a ROYAL BOLTON HOSPITAL   (United Kingdom)

^b RIVERS STATE UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Nigeria)

Author keywords

Anti d; Management; Rh negative women; Rhesus isoimmunization; Sub saharan africa; Universal access

Indexed keywords

RHESUS D ANTIBODY;

ABDOMINAL INJURY; AFRICA; ALLOIMMUNIZATION; AMNIOCENTESIS; ANTEPARTUM HEMORRHAGE; ANTIBODY SCREENING; ARTICLE; CORDOCENTESIS; COST EFFECTIVENESS ANALYSIS; FETOMATERNAL TRANSFUSION; FETUS DEATH; FLOW CYTOMETRY; HUMAN; IMMUNOPROPHYLAXIS; OBSTETRIC CARE; PERINATAL MORBIDITY; PHENOTYPE; POSTNATAL CARE; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL CARE; PUERPERIUM; RHESUS ISOIMMUNIZATION; SPONTANEOUS ABORTION; STILLBIRTH; SUB SAHARAN AFRICA; VAGINA BLEEDING;

EID: 78650743394     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: 10.2147/IJWH.S15165     Document Type: Article

References (61)

1. Knowles S, Poole G. Human blood group systems. In: Murphy MF, Pamphilon DH, editors. Practical Transfusion Medicine. 1st ed. London, UK: Blackwell Science; 2002:24-31.
2. Jeremiah Z.A. An assessment of the clinical utility of routine antenatal screening of pregnant women at first clinic attendance for haemoglobin genotypes, haematocrit, ABO and Rh blood groups in Port Harcourt, Nigeria. Afr J Reprod Health. 2005;9:112-117.
3. Mwangi J. Blood groups distribution in an urban population of patient targeted blood donors. East Afr Med J. 1999;76:615-618.
4. Loua A, Lamah MR, Haba NY, Camara M. Frequency of blood groups ABO and rhesus D in the Guinean population. Transfus Clin Biol. 2007; 14:435-439.
5. Tagny CT, Fongué VF, Mbanya D. The erythrocyte phenotype in ABO and Rh blood groups in blood donors and blood recipients in a hospital setting of Cameroon: adapting supply to demand. Rev Med Brux. 2009;30: 159-162.
6. Bergstrom S, Pereira C, Hagstrom U, Safwenberg J. Obstetric implications of rhesus antigen distribution in Mozambican and Swedish women. Gynecol Obstet Invest. 1994;38:82-86.
7. Correa P, Linhard J, Diebolt G, Diadhiou F. Study of bilirubin in amniotic fluid associated with fetomaternal isoimmunization at Dakar. Bull Soc Med Afr Noire Lang Fr. 1969;14:262-266.
8. Verkuyl DA. Economics of anti-rhesus prophylaxis in an African population. Cent Afr J Med. 1987;33:32-37.
9. Hitzeroth HW, Op't Hof J. On the prevention of rhesus immunization in the RSA. S Afr Med J. 1988;19;74:502-506.
10. Pereira C, Axemo P, Bergström S, Säfwenberg J. Parity-related prevalence of rhesus antigens among Mozambican parturients. Gynecol Obstet Invest. 1992;34:129-132.
11. Cakana AZ, Ngwenya L. Is antenatal antibody screen worthwhile in the Zimbabwean Population? Cent Afr J Med. 2001;47:26-28.
12. Kotila TR, Odukogbe AA, Okunlola MA, Olayemi O, Obisesan KA. The pregnant Rhesus negative Nigerian woman. Niger Postgrad Med J. 2005;12:305-307.
13. Toure Ecre A, Horo FM, Sein K, Konan Ble R, Kone M. Management of rhesus alloimmunisation by spectrophometry: about one case at the Yopougon Teaching Hospital, Côte-d'Ivoire. Bull Soc Pathol Exot. 2006;99:245-249.
14. Darmstadt GL, Lee AC, Cousens S, et al. 60 Million non-facility births: who can deliver in community settings to reduce intrapartum-related deaths? Int J Gynaecol Obstet. 2009;107 Suppl 1:S89-S112.
15. Belinga S, Ngo Sack F, Bilong C, Manga J, Mengue MA, Tchendjou P. High prevalence of anti-D antibodies among women of childbearing age at Centre Pasteur of Cameroon. Afr J Reprod Health. 2009;13:47-52.
16. Cortey A, Brossard Y. Prevention of fetomaternal rhesus-D alloimmunization. Practical aspects. J Gynecol Obstet Biol Reprod (Paris). 2006;35 Suppl 1:1S123-1S130.
17. Urbaniak S. The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol. 1998;105:11-18.
18. Fung Kee Fung K, Eason E, Crane J, et al; Maternal-Fetal Medicine Committee, Genetics Committee. Prevention of Rh alloimmunization. J Obstet Gynaecol Can. 2003;25:765-773.
19. Beliard R. Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. Transfus Clin Biol. 2006;13:58-64.
20. Harrod KS, Hanson L, VandeVusse L, Heywood P. Rh negative status and isoimmunization update: a case-based approach to care. J Perinat Neonatal Nurs. 2003;17:166-178.
21. Hensleigh PA. Preventing rhesus isoimmunization. Antepartum Rh immune globulin prophylaxis versus a sensitive test for risk identification. Am J Obstet Gynecol. 1983;146:749-755.
22. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 2007;93:99-111.
23. Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program. 2009:185-191.
24. Weinstein L. Irregular antibodies causing haemolytic disease of the newborn: a continuing problem. Clin Obstet Gynecol. 1982;25:321-332.
25. Bowman J. Hemolytic disease (erythroblastosis fetalis). In: Creasy R, Resnik R, editors. Prevention of Rh alloimmunization. Philadelphia, PA: WB Saunders Co.; 1999:736-738.
26. Hatwell E. Use of Rh immune globulin. ASCP Practice Parameter. Am J Clin Pathol. 1998;110:281-302.
27. Tovey LAD. Towards the conquest of Rh haemolytic disease: Britain's contribution and the role of serendipity. Transfus Med. 1992;2: 99-109.
28. MacKenzie IZ, Bowell P, Gregory H, Pratt G, Guest C, Entwistle CC. Routine antenatal rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. Br J Obstet Gynaecol. 1999;106:492-497.
29. National Institute for Clinical Excellence. Technology appraisal guidance 41. Guidance on the Use of Routine Antenatal Anti-D Prophylaxis for RhD-negative Women. London, UK: NICE; 2002.
30. Harkness M, Freer Y, Prescott RJ, Warner P. Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: a survey of UK maternity units. Transfus Med. 2008;18:292-295.
31. Mitchell R, Bowell P, Letsky E, de Silva M, Whittle M. Guidelines for blood grouping and red cells antibody testing during pregnancy. Transfus Med. 1996;6:7-74.
32. Avent ND. RHD genotyping from maternal plasma: guidelines and technical challenges. Methods Mol Biol. 2008;444:185-201.
33. Daniels G, Finning K, Martin P, Summers J. Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin. Transfus Clin Biol. 2007;14:568-571.
34. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ. 2008;336:816-818.
35. Carroli G, Rooney C, Villar J. How effective is antenatal care in preventing maternal mortality and serious morbidity? An overview of the evidence. Paediatr Perinat Epidemiol. 2001;15:1-42.
36. Ahman E, Shah I. Unsafe abortion: worldwide estimates for 2000. Reprod Health Matters. 2002;10:13-17.
37. Rogo KO. Induced abortion in sub-Saharan Africa. East Afr Med J. 1993; 70(6):386-395.
38. Bio Products Laboratory. The clinical and cost effectiveness of routine antenatal prophylaxis for rhesus negative women in pregnancy. A submission to the National Institute for Clinical Excellence, 2001.
39. Baxter Healthcare. The clinical and cost effectiveness of anti-D prophylaxis for Rhesus negative women in pregnancy. Submission to the National Institute for Clinical Excellence, 2001.
40. Chilcott J, Tappenden Pl, Lloyd Jones M, et al. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative. Br J Obstet Gynaecol. 2004;111:903-907.
41. Tagny CT, Mbanya D, Tapko JB, Lefrère JJ. Blood safety in Sub-Saharan Africa: a multi-factorial problem. Transfusion. 2008;48:1256-1261.
42. Ouwehand WH, Goodyear E, Camilleri-Ferrante C, Burgess C, Rankin A. Epidemiology of RhD haemolytic disease of the newborn in East Anglia. Br J Obstet Gynaecol. 1998;105:23-24.
43. Hudon L, Moise KJ Jr, Hegemier SE, Hill RM, Moise AA, Smith EO, et al. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal haemolytic disease. Am J Obstet Gynecol. 1998;179:858-863.
44. Chaffe B, Ford J, Bills V. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen. Transfus Med. 2007;17: 399-403.
45. Pilgrim H, Lloyd-Jones M, Rees A. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Health Technol Assess. 2009;13:120-126.
46. Boudhraa K, Mammou S, Ben Salah N, Gara MF. Red-cell alloimmunization: prevention and management. Tunis Med. 2009;87:240-245.
47. Koelewijn JM, Vrijkotte TG, de Haas M, van der Schoot CE, Bonsel GJ. Women's attitude towards prenatal screening for red blood cell antibodies, other than RhD. BMC Pregnancy Childbirth. 2008;11:49.
48. Koelewijn JM, de Haas M, Vrijkotte TG, van der Schoot CE, Bonsel GJ. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. Br J Obstet Gynaecol. 2009;116:1307-1314.
49. Hensleigh PA. Preventing rhesus isoimmunization. Antepartum Rh immune globulin prophylaxis versus a sensitive test for risk identification. Am J Obstet Gynecol. 1983;146:749-755.
50. Wee WW, Kanagalingam D. The use of anti-D immunoglobulins for rhesus prophylaxis: audit on knowledge and practices among obstetricians. Singapore Med J. 2009;50:1054-1057.
51. Katiyar R, Kriplani A, Agarwal N, Bhatla N, Kabra M. Detection of fetomaternal hemorrhage following chorionic villus sampling by Kleihauer Betke test and rise in maternal serum alpha feto protein. Prenat Diagn. 2007;27:139-142.
52. NHS Evidence. Guidelines for the estimation of fetomaternal haemorrhage. Working Party of the British Committee for Standards in Haematology, Tranfusion Taskforce; 2009. Available from: http://www.bcshguidelines.com/documents/BCSH_FMH_bcsh_sept2009.pdf. Accessed 2010 Nov 10.
53. Robson SC, Lee D, Urbaniak S. Anti-D immunoglobulin in RhD prophylaxis. Br J Obstet Gynaecol. 1998;105:129-134.
54. British Committee for Standards in Haematology (BCSH 2006). Guidelines for the use of prophylactic anti-D immunoglobulin. Available from: http://www.bcshguidelines.org/. Accessed 2010 Nov 10.
55. Howarth DJ, Robinson FM, Williams M, Norfolk DR. A modified Kleihauer technique for the quantification of fetomaternal haemorrhage. Transfus Med. 2002;12:373-378.
56. Duguid JKM, Bromilow IM, Eggington J, Martlew VJ, McFadyen IR, Clarke CA. Kleihauer Testing and flow cytometry. A comparative study for assessment of feto-maternal haemorrhage. Hematology. 1996;1: 79-83.
57. Davies BH, Olsen S, Bigelow NC, Chen JC. Detection of fetal red cells in fetomaternal hemorrhage using a fetal haemoglobin antibody by flow cytometry. Transfusion. 1998;38:749-756.
58. Johnson PR, Tait RC, Austin EB, Shwe KH, Lee D. Flow cytometry in diagnosis and management of large fetomaternal haemorrhage. J Clin Pathol. 1995;48:1005-1008.
59. Radel DJ, Penz CS, Dietz AB, Gastineau DA. A combined flow cytometry-based method for fetomaternal hemorrhage and maternal D. Transfusion. 2008;48:1886-1891.
60. Gargouri J, Khemiri H, Feki H, Rekik H, Rekik S. Anti-erythrocyte alloimmunization in an obstetrical milieu. Study of 2093 cases. Tunis Med. 2002;80:255-259.
61. Hofmeyr GJ, Haws RA, Bergström S, et al. Obstetric care in lowresource settings: what, who, and how to overcome challenges to scale up? Int J Gynaecol Obstet. 2009;107 Suppl 1:S21-S44, S44-S45.